Observed costs and health care use of children in a prospective cohort study on community-acquired pneumonia in Geneva, Switzerland

Observed costs and health care use of children in a prospective cohort study on community-acquired pneumonia in Geneva, Switzerland

QUESTIONS UNDER STUDY: Despite various efforts to estimate cost-effectiveness of pneumococcal conjugate vaccines, only scarce information on the cost burden of paediatric community acquired pneumonia (CAP) exists. The objective of this study was to prospectively calculate direct and indirect c...

Full description

Bibliographic Details
Main Authors:	Kristina Keitel, Gabriel Alcoba, Laurence Lacroix, Sergio Manzano, Annick Galetto-Lacour, Alain Gervaix
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2014-03-01
Series:	Swiss Medical Weekly
Subjects:	pneumonia community acquired pneumonia costs pneumococcal vaccines
Online Access:	https://www.smw.ch/index.php/smw/article/view/1846

Similar Items

Community acquired paediatric pneumonia; experience from a pneumococcal vaccine- naive population
by: Sanath Thushara Kudagammana, et al.
Published: (2020-08-01)

23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type <i>Streptococcus pneumoniae</i>
by: Thomas Chandler, et al.
Published: (2022-03-01)

Fatal Community-Acquired Pneumonia: 18 Years in a Medical Center
by: Ling-Jen Wang, et al.
Published: (2013-02-01)

Effect of vaccination on morbidity and mortality from community-acquired pneumonia
by: T. A. Bayanova, et al.
Published: (2024-03-01)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
by: Ching-Fen Shen, et al.
Published: (2021-09-01)

Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study
by: Rosario Menéndez, et al.
Published: (2023-11-01)

Comparison of prognostic factors between bacteraemic and non-bacteraemic critically ill immunocompetent patients in community-acquired severe pneumococcal pneumonia: a STREPTOGENE sub-study
by: Hugo Bellut, et al.
Published: (2021-10-01)

A model for predicting bacteremia in patients with community-acquired pneumococcal pneumonia: a retrospective observational study
by: Yasuyoshi Washio, et al.
Published: (2018-01-01)

Is it not the Time to Use Urine Pneumococal Antigen Test for the Diagnosis of Community-Acquired Pneumonia
by: M. Rıdvan DUMLU, et al.
Published: (2021-03-01)

Evaluation of Plasma Lipocalin-2 as a Predictor of Etiology and Severity in Adult Patients with Community-Acquired Pneumonia
by: Lucía Boix-Palop, et al.
Published: (2023-04-01)

Prevalence of Pneumococcal Serotypes in Community-Acquired Pneumonia among Older Adults in Italy: A Multicenter Cohort Study
by: Andrea Orsi, et al.
Published: (2022-12-01)

Radiographically confirmed community-acquired pneumonia in hospitalized adults due to pneumococcal vaccine serotypes in Sweden, 2016–2018—The ECAPS study
by: Karin Hansen, et al.
Published: (2023-02-01)

Risk of community acquired pneumonia in patients with diabetes mellitus: Review
by: Galina L. Ignatova, et al.
Published: (2022-03-01)

Age-related differences in management and outcomes in hospitalized healthy and well-functioning bacteremic pneumococcal pneumonia patients: a cohort study
by: Luis A. Ruiz, et al.
Published: (2017-06-01)

Community-acquired pneumonia in the United Kingdom: a call to action
by: James Chalmers, et al.
Published: (2017-10-01)

Economic burden of community-acquired pneumonia among elderly patients: a Japanese perspective
by: Keiko Konomura, et al.
Published: (2017-12-01)

Features of laboratory indicators of severe community-acquired pneumonia
by: Pertzeva T.A., et al.
Published: (2017-06-01)

Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact
by: Raúl O. Ruvinsky, et al.
Published: (2018-11-01)

Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type <i>Streptococcus pneumoniae</i>. <i>Microorganisms</i> 2022, <i>10</i>, 560
by: Nicole Cossrow, et al.
Published: (2022-10-01)

Hospital Acquired Pneumonia
by: Halis AKALIN, et al.
Published: (1999-12-01)

Community-acquired pneumonia /
by: Suttorp, N. (Norbert), 1953-, et al.
Published: (2007)

Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs
by: Claire Dupuis, et al.
Published: (2021-01-01)

PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
by: Christian Theilacker, et al.
Published: (2022-01-01)

Mycoplasma pneumonia and Chlamydia pneumonia infection in patients admitted to Beheshti Hospital in Kashan with community-acquired pneumonia
by: Mansoreh Momen Heravi, et al.
Published: (2023-12-01)

Тhe features of severe community acquired pneumonia
by: Avramenko I.V.
Published: (2015-06-01)

chlamydia pneumoniae unfection in - patients with community acquired pneumonia in Iraq
by: hayfaa D. Salman
Published: (2009-01-01)

Response to “Letter to the Editor: Vaccine Failures in Pediatric Cases Caused by Streptococcus pneumoniae Serotype 19A”
by: Erdem Gönüllü, et al.
Published: (2020-10-01)

CAPPRIC Study—Characterization of Community-Acquired Pneumonia in Spanish Adults Managed in Primary Care Settings
by: Jesús Molina, et al.
Published: (2021-02-01)

PES Pathogens in Severe Community-Acquired Pneumonia
by: Catia Cillóniz, et al.
Published: (2019-02-01)

Dilemma of community-acquired pneumonia
by: Lamia H Shaaban
Published: (2019-01-01)

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany
by: Felicitas Kühne, et al.
Published: (2023-12-01)

Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey
by: Erdem Gönüllü, et al.
Published: (2020-10-01)

Pattern of community and hospital acquired pneumonia in Egyptian military hospitals
by: Magdy Mohammad Khalil, et al.
Published: (2013-01-01)

Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators
by: Catia Cillóniz, et al.
Published: (2020-01-01)

The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia
by: E. Blanc, et al.
Published: (2021-09-01)

Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging
by: Catia Cillóniz, et al.
Published: (2018-04-01)

Influence of pneumococcal vaccination on the hospitalization of healthy pediatric patients due to typical Community-Acquired Pneumonia
by: Ana Isabel Valdivielso Martínez, et al.
Published: (2020-09-01)

Economic aspects of hospital treated pneumococcal pneumonia and the results of Pneumo 23 vaccine use in Serbia
by: Adžić Tatjana, et al.
Published: (2008-01-01)

Mycoplasma pneumoniae: Atypical Pathogen in Community Acquired Pneumonia
by: Abdul-Rahman Mamdouh Mohammad, et al.
Published: (2020-12-01)

Cytokine profile in community-acquired pneumonia in children
by: N. V. Iziurova, et al.
Published: (2022-11-01)